Abstracts tagged "takayasu arteritis and treatment"

Abstract Number: 811 • 2014 ACR/ARHP Annual Meeting
Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Arsene Mekinian¹, Chloe Comarmond², Mathieu Resche Regon³, Tristan Mirault⁴, Jean-Emmanuel Kahn⁵, Marc Lambert⁶, Jean Sibilia⁷, Antoine Neel⁸, Miguel Hié⁹, Emmanuel Messas¹⁰, Pascal Cohen¹¹, Geraldine Muller¹², Sabine Berthier¹³, Zahir Amoura¹⁴, Isabelle Marie¹⁵, Christian Lavigne¹⁶, Marie Anne Vandenhende¹⁷, Hervé Devilliers¹⁸, Sébastien Abad¹⁹, Loic Guillevin²⁰, Mohamed Hamidou²¹, Bertrand Godeau²², Patrice Cacoub²³, Olivier Fain²⁴ and David Saadoun², ¹DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France, ²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ³biostatistics Saint Louis Hospital, paris, France, ⁴HEGP vascular department, paris, France, ⁵Internal Medicine, Foch Hospital, Suresnes, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸INTERNAL MEDICINE, NANTES, France, ⁹Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹⁰HEGP hospital Vascular and cardiology Department, paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²INTERNAL MEDICINE, DIJON, France, ¹³DIJON HOSPITAL, DIJON, France, ¹⁴Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁵CHU de Rouen, Rouen, France, ¹⁶CHU d'Angers, Angers, France, ¹⁷Internal Medicine, Bordeaux, France, ¹⁸Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ¹⁹Hôpital Avicenne, Bobigny, France, ²⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, ²¹CHU Hôtel Dieu, Nantes, Nantes, France, ²²Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²⁴Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France
Background/Purpose The aim of this registry is to determine: (1) the real-life use of various biological targeted treatments in Takayasu arteritis (TA) in France; (2)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].